Taurus Vascular

Taurus Vascular is a private, pre-revenue medical device company targeting the significant unmet need of endoleaks in abdominal aortic aneurysm (AAA) treatment. The company's core technology is a catheter-deployed device that creates a shunt to drain and depressurize the aneurysm sac post-EVAR, aiming to prevent sac growth and rupture. Operating in a multi-billion dollar market with a high rate of complications, Taurus aims to redefine the standard of care by improving procedural durability and reducing the substantial healthcare costs associated with reinterventions. Founded in 2010 and revitalized in 2022, the company is in the development stage, building its intellectual property portfolio and advancing its first program.

Minimally invasive, catheter-based platform featuring a self-deploying stent/shunt designed to create a drainage pathway between an aortic aneurysm sac and a nearby vein to depressurize the sac and manage endoleaks.

Competition includes large incumbent EVAR graft manufacturers (e.g., Medtronic, Gore, Cook Medical) who may develop internal solutions, as well as other startups exploring endoleak management. Current standard-of-care for endoleaks involves adjunctive procedures like embolization, which are reactive and not always durable.